


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ono et al.
Serial No: 09/559,013
Filed: April 26, 2000
For: CANCER ASSOCIATED ANTIGENS AND USES THEREFOR
Examiner: Not Assigned
Art Unit: Unknown

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Box Missing Parts, Commissioner for Patents, Washington, D.C. 20231, on the 4th day of August, 2000.


Monica E. Zombori

Box Missing Parts
COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

**COPY
AS FILED**

Sir:


Transmitted herewith are the following documents:

- ☒ Preliminary Amendment
- ☒ Fee Calculation Sheet
- ☒ Copy of Notice to File Missing Parts
- ☒ Revised Sequence Listing - paper copy and identical computer readable diskette
- ☒ Statement Pursuant to 37 CFR 1.821(f) and 1.825(a) and (b)
- ☒ Check in the amount of \$2616.00
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

If the amount of the enclosed check is determined to be insufficient, the balance may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,


John R. Van Amsterdam, Reg. No. 40,212
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel.: (617) 720-3500

Docket No.: L0461/7086
Date: August 4, 2000
x9/5/00

Inventor(s): Ono et al.

Serial No: 09/559,013

Filed: April 26, 2000

For: CANCER ASSOCIATED ANTIGENS AND USES THEREFOR

CHECK BOX, if applicable:

☐ DUPLICATE

Fee Calculation Sheet

CLAIMS	FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
	TOTAL CLAIMS (37 CFR 1.16(c))	36-20=	16x	\$ 18	= \$ 288.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	19-3=	16 x	\$ 78	= \$ 1,248.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d)) +			\$260.00	= \$ 260.00
				BASIC FEE (37 CFR 1.16(a))	\$ 690.00
	Fee for Petition for Extension of Time (if any)				\$
	Total of above Calculations =				\$ 2,486.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				\$
	Assignment Recordation Fee (if any)				\$
	Other Fees (if any).				\$ 130.00
	TOTAL =				\$ 2,616.00

1. A check in the amount of \$2,616.00 is enclosed.

General Authorization to Charge Deposit Account and General Request for Extension of Time

2. a. ☒ If the filing of any paper in this application necessitates the payment of a fee under 37 CFR §§ ☒ 1.16 ☒ 1.17 or ☒ 1.18, and the fee due is in an amount different from any enclosed check or if no check is enclosed, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.

b. ☐ The applicant hereby revokes any prior authorization to charge a fee due under 37 CFR §§ ☐ 1.16 ☐ 1.17 or ☐ 1.18.

3. If the filing of any paper in this application necessitates an extension of time under 37 CFR § 1.136(a), the applicant hereby requests such extension of time. If the fee due is in an amount different from any enclosed check or if no check is enclosed, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.

John R. Van Amsterdam
 John R. Van Amsterdam, Reg. No. 40,212
 Wolf, Greenfield & Sacks, P.C.
 600 Atlantic Avenue
 Boston, MA 02210-2211
 (617) 720-3500
 Attorneys of Record

Docket No. L0461/7086 (JRV)
 Date: August 4, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ono et al.
Serial No : 09/559,013
Filed : April 26, 2000
For : CANCER ASSOCIATED ANTIGENS AND USES THEREFOR
Examiner : A. Holleran
Art Unit : 1642

CERTIFICATE OF FILING UNDER 37 C.F.R. §1.10

The undersigned hereby certifies that this document is being sent via Express Mail service of the United States Post Office, addressed to the Commissioner for Patents, Attn: Examiner Anne Holleran, United States Patent and Trademark Office, Technology Center 1600/2900, Crystal Mall 1, 7th Floor, 1911 South Clark Street, Arlington VA 22201, on the 11th day of July, 2001.


Monica E. Zombori

Commissioner for Patents

Attn: Examiner Anne Holleran

United States Patent and Trademark Office

Technology Center 1600/2900

Crystal Mall 1, 7th Floor

1911 South Clark Street

Arlington VA 22201

Sir:


Transmitted herewith are the following documents:

- ☒ Response to Notice to Comply with Sequence Rules
- ☒ Copy of Notice to Comply with Sequence Rules
- ☒ Copies of documents filed on August 4, 2000 in response to the Notice to File Missing Parts
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 720-3500, Boston, Massachusetts.

No check is enclosed. If a fee is determined to be required, the balance may be charged to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,



John R. Van Amsterdam
Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500

Docket No. L0461/7086
Dated: July 11, 2001
X08/03/01

Applicant: Ono et. al.

Title: **CANCER ASSOCIATED
ANTIGENS AND USES
THEREFOR**

Date Recorded: August 4, 2000

Operating Sys.: Windows 98

Reference No.: L0461/7086

Serial Number: 09/559,013

Filing Date: April 26, 2000


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ono et al.
Serial No : 09/559,013
Filed : April 26, 2000
For : CANCER ASSOCIATED ANTIGENS AND USES THEREFOR
Examiner : A. Holleran
Art Unit : 1642

106B
50
727-01

CERTIFICATE OF FILING UNDER 37 C.F.R. §1.10

The undersigned hereby certifies that this document is being sent via Express Mail service of the United States Post Office, addressed to the Commissioner for Patents, Attn: Examiner Anne Holleran, United States Patent and Trademark Office, Technology Center 1600/2900, Crystal Mall 1, 7th Floor, 1911 South Clark Street, Arlington VA 22201, on the 11th day of July, 2001.


Monica E. Zombori

Commissioner for Patents
Attn: Examiner Anne Holleran
United States Patent and Trademark Office
Technology Center 1600/2900
Crystal Mall 1, 7th Floor
1911 South Clark Street
Arlington VA 22201

REPLY TO NOTICE TO COMPLY WITH SEQUENCE RULES

Sir:


Applicants thank Examiner Holleran for the courtesy extended in the telephone conversation of July 11, 2001 between the Examiner and the undersigned representative of Applicants.

Applicants enclose herewith copies of the complete set of papers and computer disk filed on August 4, 2001 in response to the Notice to File Missing Parts. The papers include a revised Sequence Listing, a statement under 37 C.F.R. 1.821 and a computer readable form of the Sequence Listing.

The revised Sequence Listing addresses the issue raised by the sequence error report sent with the notice to comply with sequence rules, specifically the missing mandatory <211> elements for SEQ ID NO:21 and SEQ ID NO:22. Accordingly, Applicants respectfully request that the Examiner withdraw the requirement for a substitute Sequence Listing CRF and paper

copy, and further request that the revised Sequence Listing filed August 4, 2001 be used for examination of this application unless and until a further revision of the sequence listing is made.

Respectfully submitted,



John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Tel. (617) 720-3500

Docket No. L0461/7086

Dated: July 11, 2001

X08/03/01



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

TRV
CW

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/559,013 04/26/00 ONO

T L0461/7086(J)

EXAMINER

HM12/0703

JOHN R VAN AMSTERDAM
C/O WOLF GREENFIELD AND SACKS P C
FEDERAL RESERVE PLAZA
600 ATLANTIC AVENUE
BOSTON MA 02210-2211

HOLLERAN, A

ART UNIT

PAPER NUMBER

1642

DATE MAILED:

07/03/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

File Folder	<input checked="" type="checkbox"/>	initials
ECB	<input checked="" type="checkbox"/>	
Docket Entry	<input checked="" type="checkbox"/>	8-3-01
Docket Cross Off	<input checked="" type="checkbox"/>	
Order Copies	<input checked="" type="checkbox"/>	
Annuities	<input type="checkbox"/>	
Confirmation	<input type="checkbox"/>	

DOCKETED

JUL 10 2001



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
	9

DATE MAILED:

Please find below a communication from the **EXAMINER** in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Any inquiry concerning this communication should be directed to Examiner **Anne Holleran**, Art Unit **1642**, whose telephone number is **703 308-8892**.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

ANTHONY C. CAPUTA
SUPERIOR PATENT EXAMINER
TECHNOLOGY CENTER 1600

Application No.: 09/559,013

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE